Pirarubicin
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | L01DB08 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
| |
Synonyms | (9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione |
CAS Number | 72496-41-4 |
PubChem (CID) | 3033521 |
ChemSpider | 2298189 |
UNII | D58G680W0G |
KEGG | D01885 |
ChEMBL | CHEMBL1398373 |
Chemical and physical data | |
Formula | C32H37NO12 |
Molar mass | 627.63 g/mol |
3D model (Jmol) | Interactive image |
Melting point | 188 to 192 °C (370 to 378 °F) (decomposes) |
| |
| |
(what is this?) (verify) |
Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.